Aloxi

Type: Product

Name: Aloxi

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose..

Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of N...LUGANO, Switzerland and WOODCLIFF LAKE, New Jersey, May 16, 2013 /PRNewswire/ --Data to Be Presented at Annual Meeting of the ... [Published ADVFN India - May 16 2013]

Entities: Eisai Inc., investigational, Palo (United States), Chemotherapy, Aloxi

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Eisai Co Ltd

Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review - new company profile report

Eisai Co., Ltd. (Eisai) is a human healthcare company. It focuses on the research, development, manufacture and commercialization of prescription pharmaceuticals and consumer health products, generic drugs and diagnostics. The company focuses its product ... [Published TransWorldNews - Apr 22 2013]

Entities: Eisai Co Ltd, SWOT Analysis, Corporate Strategy, Fragmin, Aloxi

First reported Apr 11 2013 - Updated Apr 11 2013 - 1 reports

TESARO Inc

Tesaro's Rolapitant: Investors Pay 17x Premium For Discarded Drug

By Apsara Biotechnology Research/a>: Tesaro ( TSRO ) has quietly been one of the top performing stocks of the past six months. After a lackluster IPO in June 2012 and subsequent dip in its share price, Tesaro has seen shares nearly double. However, ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 11 2013]

Entities: TESARO Inc, Drugs, Anzemet, Aloxi, Aprepitant

First reported Dec 05 2012 - Updated Dec 06 2012 - 1 reports

Human medicines European Public Assessment Report (EPAR): Aloxi, palonosetron, Revision: 15, Authorised

[Published Pending EC decisions and European Public Assess ... - Dec 05 2012]

Entities: Aloxi

Quotes

"We are very excited to have commenced this important study," said Dr. Isaacson. "We hope to show that APOKYN will provide a valuable treatment option for Parkinson s disease patients with morning akinesia due to delayed onset of levodopa by rapidly and reliably restoring their motor function and enabling them to get on with their day. We plan to have initial results available in August."

New clinical trial investigates APOKYN for treating debilitating morning akinesia in Parkinson’s ... [Published Business Wire - May 13 2013]

...7,700,365 ("Vitamin D Deficiencies," issued April 20, 2010), 7,901,944 (same title, issued March 8, 2011), and 8,349,613 ( "Mass Spectroscopy Techniques for Detecting Vitamin D Compounds in a Sample" issued January 8, 2013) based on ARUP's diagnostic testing referred to as "25-Hydroxyvitamin D2 and D3 by Tandem Mass Spectrometry...

Court Report - April 28, 2013 [Published JD Supra - Apr 29 2013]

...researchandmarkets.com/research/d34lgb/cinv_existing_and) has announced the addition of the "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron Fdc, Apf530 & Rolapitant) - Global Market Opportunity Assessment Study, 2012 - 2018" report to their offering...

Research and Markets: CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron Fdc, ... [Published Business Wire Health News - Nov 28 2012]

70 pacientes australianos implicaron en este ensayo comparativo con ABRAXANE frente al agente de quimioterapia est$ndar actual con dacarbazina. "El melanoma metast$tico presenta un reto de tratamiento importante, debido en parte a las terapias limitadas existentes, bajas tasas de supervivencia en su diagnosis y a los avances no existentes en la quimioterapia en 37 a$os" , coment$ el doctor Evan M Hersh

ABRAXANE® demuestra una mejora destacada en la supervivencia libre de progresión frente a la quim ... [Published PR Newswire - Oct 26 2012]

More Content

sort by: Date \| Relevance
Helsinn Group and Eisai Inc. Announce Top-Line ... [Published ADVFN India - May 16 2013]
New clinical trial investigates APOKYN for trea... [Published Business Wire - May 13 2013]
Netupitant Results Could Roil Tesaro In May [Published Seeking Alpha - May 06 2013]
Court Report - April 28, 2013 [Published JD Supra - Apr 29 2013]
Eisai Co., Ltd. (4523) - Financial and Strategi... [Published TransWorldNews - Apr 22 2013]
Tesaro's Rolapitant: Investors Pay 17x Premium ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 11 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Dec 05 2012]
Research and Markets: CINV Existing & Pipeline ... [Published Business Wire Health News - Nov 28 2012]
Chemotherapy Induced Nausea and Vomiting (CINV)... [Published PR Newswire: General Business - Nov 28 2012]
ABRAXANE® demuestra una mejora destacada en la ... [Published PR Newswire - Oct 26 2012]
STA inks commercialisation pact with Helsinn fo... [Published PharmaBiz - Oct 16 2012]